Red blood cell drug-loaded microparticle and application thereof

By using red blood cells to prepare drug-loaded microparticles without nucleic acids, the problem of the risk of nucleic acid delivery in tumor treatment is solved, the dual role of chemotherapy and immunotherapy is achieved, the efficacy is improved and the preparation process is simplified.

CN118903040AInactive Publication Date: 2024-11-08XINXIANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410973907.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing drug-loaded microparticles may carry nucleic acids of the breast in tumor treatment, leading to risk of gene recombination and mutation, and the preparation process is complex and inefficient.

Method used

Red blood cells are used as carriers to prepare drug-carrying microparticles without nucleic acids through electroporation and ultraviolet irradiation, simplifying the preparation process and improving efficiency.

Benefits of technology

It avoids the potential harm caused by nucleic acid delivery, realizes the dual role of chemotherapy and immunotherapy, improves the efficacy of tumor treatment, simplifies the preparation process, and reduces costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903040A_ABST
    Figure CN118903040A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, in particular to erythrocyte drug-loaded microparticles and application thereof. The red blood cell drug-loaded microparticles are prepared according to the following steps: treating a red blood cell suspension by using an electroporation method, and adding a drug to obtain a mixture; irradiating the mixture with ultraviolet rays, culturing after irradiation to enable the red blood cells to release the drug-loaded microparticles, and performing differential centrifugation to obtain the red blood cell drug-loaded microparticles. The red blood cells used in the method are convenient to obtain and do not need to be subjected to in-vitro amplification culture, so that the cost and time are saved; the drug-loaded microparticles prepared from red blood cells do not contain nucleic acid, so that potential hazards caused by the fact that drug-loaded microparticles prepared from other types of cells carry mother cell nucleic acid are avoided; the red blood cell drug-loaded microparticle provided by the invention not only can directly kill tumor cells, but also can chemotactic neutrophils of an organism to participate in anti-tumor immune response, so that tumor treatment is more efficient.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to red blood cell drug-loaded microparticles and applications thereof. Background Art

[0002] Tumors pose a serious threat to human health. Traditional tumor treatments, such as chemotherapy and radiotherapy, have strong side effects and are prone to recurrence after treatment. Emerging tumor immunotherapy provides a new approach to tumor treatment, but the therapeutic effect of tumor immunotherapy on most tumors is not satisfactory. How to combine tumor immunotherapy with traditional tumor treatment methods to improve the efficacy is an urgent problem to be solved.

[0003] In recent years, extracellular vesicles have become a hot topic in various studies as a carrier for the exchange of substances, energy and information between cells. Microparticles (MP) are a type of extracellular vesicles. When cells receive various stimulations or apoptosis signals, the cell membrane wraps part of the cell's proteins, lipids, nucleic acids and other components to form a vesicle-like structure with a diameter between 100nm and 1000nm.

[0004] MP can be used as a carrier of chemotherapy drugs to deliver chemotherapy drugs to the tumor site, effectively killing tumor cells while reducing the side effects of chemotherapy drugs. The cells used to prepare drug-loaded microparticles include tumor cells, mesenchymal stem cells, macrophages, dendritic cells and other cell types. These cells generally have the disadvantages of being difficult to obtain, having a small number in the body, and having a long in vitro expansion culture cycle. In addition, MP carries nucleic acid fragments such as DNA and RNA, which are genetic materials derived from mother cells. The reintroduction of nucleic acid fragments into the human body by drug-loaded microparticles may cause genetic recombination and mutation of the recipient cells, and even induce tumors. This long-term risk is an unavoidable problem for common drug-loaded microparticles. Summary of the invention

[0005] To solve the above problems, the present invention provides a red blood cell drug-loaded microparticle, which does not contain nucleic acid, thereby avoiding the potential harm caused by microparticles prepared from other types of cells carrying mother cell nucleic acid and delivering nucleic acid to recipient cells during tumor treatment.

[0006] In a first aspect, the present invention provides a red blood cell drug-loaded microparticle, which is prepared according to the following steps:

[0007] Treating a suspension of red blood cells by electroporation, adding a drug, and obtaining a mixture;

[0008] irradiating the mixture with ultraviolet light, culturing after irradiation to allow the red blood cells to release the drug-loaded microparticles, and performing differential centrifugation to obtain red blood cell drug-loaded microparticles;

[0009] The electroporation treatment is performed by using a square wave at a voltage of 200V to 300V, and the ultraviolet irradiation is performed at an intensity of 280J / m 2 ~330J / m 2 Irradiate for 1h~1.5h;

[0010] Among them, the red blood cell suspension is derived from the ex vivo peripheral blood of animals or humans.

[0011] As a preferred embodiment of the present invention, the ultraviolet irradiation intensity is 300 J / m 2 , the irradiation time is 1.5h.

[0012] As a preferred embodiment of the present invention, the parameters for treating the red blood cell suspension by electroporation are set as: square wave, voltage 200V-300V, time 5ms-10ms, number of electric shocks 5-8 times, and interval time 7s-10s.

[0013] As a preferred embodiment of the present invention, the culturing is carried out in a carbon dioxide incubator for 18 hours to 24 hours.

[0014] As a preferred embodiment of the present invention, the drug is doxorubicin (DOX) or methotrexate (MTX).

[0015] More preferably, the concentration of the red blood cell suspension is 3×10 8 / mL~5×10 8 / mL, the volume ratio of DOX with a mass concentration of 5mg / mL to 10mg / mL or MTX with a mass concentration of 40mg / mL to 50mg / mL to the red blood cell suspension is 4-5:3.5-4.

[0016] As a preferred embodiment of the present invention, the electroporated red blood cell suspension is diluted with RPMI 1640 culture medium before adding the drug, the RPMI 1640 culture medium contains 10% fetal bovine serum, and the volume ratio of the RPMI 1640 culture medium to the red blood cell suspension is 300-350:3.5-4.

[0017] As a preferred embodiment of the present invention, the differential centrifugation is carried out according to the following steps:

[0018] The culture medium is centrifuged at 1800×g-2000×g and 4°C for 10min-15min to remove red blood cells; the supernatant is taken and centrifuged at 13000×g-14000×g and 4°C for 2min-5min to remove cell debris; the supernatant is taken and centrifuged at 13000×g-14000×g and 4°C for 1h-1.5h, and the resulting precipitate is the red blood cell drug-loaded microparticles.

[0019] In a second aspect of the present invention, a composition is provided, wherein the red blood cell drug-loaded microparticles are described. The composition may also include other excipients or carriers to prepare the composition into a pharmaceutical preparation suitable for clinical needs. The type and amount of the specific excipients or carriers can be selected according to the preparation to be prepared, and the preparation can be prepared according to conventional pharmaceutical methods.

[0020] The third aspect of the present invention provides a use of the red blood cell drug-loaded microparticles or the composition in the preparation of anti-tumor drugs.

[0021] The fourth aspect of the present invention provides a use of the red blood cell drug-loaded microparticles or the composition in the preparation of a drug for stimulating an immune response in a tumor patient.

[0022] Compared with the existing drug-loaded microparticles and preparation methods, the present invention has the following beneficial effects:

[0023] 1. The drug-loaded microparticles prepared from red blood cells do not contain nucleic acids, thus avoiding the potential harm caused by drug-loaded microparticles prepared from other types of cells carrying mother cell nucleic acids and delivering nucleic acids to recipient cells during tumor treatment.

[0024] 2. Red blood cell drug-loaded microparticles can not only directly kill tumor cells, but also mobilize the body's immune cells to participate in anti-tumor immune response, play a dual role of chemotherapy and immunotherapy, and improve the efficacy.

[0025] 3. The present invention simplifies the steps of preparing drug-loaded microparticles by conventional electroporation methods, such as eliminating the step of co-incubating drugs and red blood cells; at the same time, it optimizes the preparation method and improves the preparation efficiency.

[0026] 4. The erythrocyte drug-loaded microparticles provided by the present invention are easy to obtain and have a large number of erythrocytes in the body. This makes the raw materials of the erythrocyte drug-loaded microparticles very easy to obtain, and does not require in vitro expansion culture, saving time and reducing costs. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 is the particle size distribution of red blood cell drug-loaded microparticles;

[0028] Figure 2 This is a transmission electron microscopic photo of red blood cell drug-loaded microparticles;

[0029] Figure 3 The drug loading conditions of red blood cell drug-loaded microparticles prepared by two methods;

[0030] Figure 4 It is the situation of nucleic acid carried in red blood cell drug-loaded microparticles;

[0031] Figure 5Figure 2 shows the situation of tumor cells engulfing red blood cell drug-loaded microparticles; A, DOX@EMP; B, MTX@EMP;

[0032] Figure 6 The killing of tumor cells by red blood cell drug-loaded microparticles;

[0033] Figure 7 is the survival period of tumor-bearing mice treated with red blood cell-loaded microparticles;

[0034] Figure 8 It is the chemotactic effect of red blood cell drug-loaded microparticles on neutrophils;

[0035] Fig. 9 It is the killing effect of neutrophils chemotactic by red blood cell drug-loaded microparticles on tumor cells. DETAILED DESCRIPTION

[0036] The specific implementation of the present invention is described in detail below, but it should be understood that the protection scope of the present invention is not limited by the specific implementation. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0037] The experimental methods described in the embodiments of the present invention are conventional methods unless otherwise specified.

[0038] The red blood cell suspensions in Examples 1 to 14 of the present invention are obtained according to the following steps:

[0039] Take the blood from the mouse, transfer it into a 15mL centrifuge tube, and dilute it with 10mL of saline. Centrifuge at 2000×g for 5 minutes, and blood cells will be seen sinking to the bottom of the tube. Discard the upper layer of liquid, the middle layer of white blood cells and platelets, and the bottom of the tube is the red blood cells. After counting the red blood cells, dilute it with saline to obtain a red blood cell suspension.

[0040] Example 1

[0041] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0042] S1, take 400 μL of 3×10 8 Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 300V, time 8ms, electric shock number 8 times, interval time 10s;

[0043] S2. Dilute the red blood cell suspension with 30 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 500 μL of 10 mg / mL DOX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (300 J / m 2 ) for 1.5 h;

[0044] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 20 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0045] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 2000 × g at 4°C for 10 min to remove erythrocytes; take the supernatant, centrifuge at 14000 × g at 4°C for 2 min to remove cell debris; take the supernatant, centrifuge at 14000 × g at 4°C for 1 h, wash the precipitate twice with physiological saline to obtain DOX-loaded erythrocyte-derived microparticle (DOX@EMP).

[0046] Example 2

[0047] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0048] S1, take 400 μL of 3×10 8 Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 200V, time 10ms, electric shock times 5 times, interval time 10s;

[0049] S2. Dilute the red blood cell suspension with 30 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 500 μL of 10 mg / mL DOX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (300 J / m 2 ) for 1.5 h;

[0050] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 20 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0051] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 2000 × g at 4°C for 10 min to remove red blood cells; take the supernatant, centrifuge at 14000 × g at 4°C for 2 min to remove cell debris; take the supernatant, centrifuge at 14000 × g at 4°C for 1 h, wash the precipitate twice with physiological saline to obtain DOX@EMP.

[0052] Example 3

[0053] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0054] S1, take 400 μL of 3×10 8 Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 250V, time 5ms, electric shock number 8 times, interval time 7s;

[0055] S2. Dilute the red blood cell suspension with 30 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 500 μL of 10 mg / mL DOX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (300 J / m 2 ) for 1.5 h;

[0056] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 20 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0057] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 2000 × g at 4°C for 10 min to remove red blood cells; take the supernatant, centrifuge at 14000 × g at 4°C for 2 min to remove cell debris; take the supernatant, centrifuge at 14000 × g at 4°C for 1 h, wash the precipitate twice with physiological saline to obtain DOX@EMP.

[0058] Example 4

[0059] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0060] S1, take 400 μL of 3×10 8 Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 300V, time 8ms, electric shock number 8 times, interval time 10s;

[0061] S2. Dilute the red blood cell suspension with 30 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 500 μL of 10 mg / mL DOX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (280 J / m 2 ) for 1 h;

[0062] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 20 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0063] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 2000 × g at 4°C for 10 min to remove red blood cells; take the supernatant, centrifuge at 14000 × g at 4°C for 2 min to remove cell debris; take the supernatant, centrifuge at 14000 × g at 4°C for 1 h, wash the precipitate twice with physiological saline to obtain DOX@EMP.

[0064] Example 5

[0065] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0066] S1, take 400 μL of 3×10 8 Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 300V, time 8ms, electric shock number 8 times, interval time 10s;

[0067] S2. Dilute the red blood cell suspension with 30 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 500 μL of 10 mg / mL DOX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (330 J / m 2 ) for 1.5 h;

[0068] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 20 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0069] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 2000 × g at 4°C for 10 min to remove red blood cells; take the supernatant, centrifuge at 14000 × g at 4°C for 2 min to remove cell debris; take the supernatant, centrifuge at 14000 × g at 4°C for 1 h, wash the precipitate twice with physiological saline to obtain DOX@EMP.

[0070] Example 6

[0071] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0072] S1, take 400 μL of 3×10 8Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 300V, time 8ms, electric shock number 8 times, interval time 10s;

[0073] S2. Dilute the red blood cell suspension with 30 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 500 μL of 10 mg / mL DOX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (300 J / m 2 ) for 1.5 h;

[0074] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 18 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0075] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 2000 × g at 4°C for 10 min to remove red blood cells; take the supernatant, centrifuge at 14000 × g at 4°C for 2 min to remove cell debris; take the supernatant, centrifuge at 14000 × g at 4°C for 1 h, wash the precipitate twice with physiological saline to obtain DOX@EMP.

[0076] Example 7

[0077] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0078] S1, take 400 μL of 3×10 8 Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 300V, time 8ms, electric shock number 8 times, interval time 10s;

[0079] S2. Dilute the red blood cell suspension with 30 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 500 μL of 10 mg / mL DOX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (300 J / m 2 ) for 1.5 h;

[0080] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 24 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0081] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 2000 × g at 4°C for 10 min to remove red blood cells; take the supernatant, centrifuge at 14000 × g at 4°C for 2 min to remove cell debris; take the supernatant, centrifuge at 14000 × g at 4°C for 1 h, wash the precipitate twice with physiological saline to obtain DOX@EMP.

[0082] Example 8

[0083] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0084] S1, take 400 μL of 3×10 8 Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 300V, time 8ms, electric shock number 8 times, interval time 10s;

[0085] S2. Dilute the red blood cell suspension with 30 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 500 μL of 5 mg / mL DOX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (300 J / m 2 ) for 1.5 h;

[0086] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 20 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0087] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 2000 × g at 4°C for 10 min to remove red blood cells; take the supernatant, centrifuge at 14000 × g at 4°C for 2 min to remove cell debris; take the supernatant, centrifuge at 14000 × g at 4°C for 1 h, wash the precipitate twice with physiological saline to obtain DOX@EMP.

[0088] Example 9

[0089] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0090] S1, take 350 μL of 3×10 8 Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 300V, time 8ms, electric shock number 8 times, interval time 10s;

[0091] S2. Dilute the red blood cell suspension with 30 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 400 μL of 10 mg / mL DOX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (300 J / m 2 ) for 1.5 h;

[0092] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 20 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0093] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 2000 × g at 4°C for 10 min to remove red blood cells; take the supernatant, centrifuge at 14000 × g at 4°C for 2 min to remove cell debris; take the supernatant, centrifuge at 14000 × g at 4°C for 1 h, wash the precipitate twice with physiological saline to obtain DOX@EMP.

[0094] Example 10

[0095] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0096] S1, take 400 μL of 5×10 8 Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 300V, time 8ms, electric shock number 8 times, interval time 10s;

[0097] S2. Dilute the red blood cell suspension with 30 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 500 μL of 10 mg / mL DOX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (300 J / m 2 ) for 1.5 h;

[0098] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 20 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0099] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 2000 × g at 4°C for 10 min to remove red blood cells; take the supernatant, centrifuge at 14000 × g at 4°C for 2 min to remove cell debris; take the supernatant, centrifuge at 14000 × g at 4°C for 1 h, wash the precipitate twice with physiological saline to obtain DOX@EMP.

[0100] Embodiment 11

[0101] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0102] S1, take 400 μL of 4×10 8 Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 300V, time 8ms, electric shock number 8 times, interval time 10s;

[0103] S2. Dilute the red blood cell suspension with 35 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 500 μL of 10 mg / mL DOX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (300 J / m 2 ) for 1.5 h;

[0104] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 20 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0105] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 2000 × g at 4°C for 10 min to remove red blood cells; take the supernatant, centrifuge at 14000 × g at 4°C for 2 min to remove cell debris; take the supernatant, centrifuge at 14000 × g at 4°C for 1 h, wash the precipitate twice with physiological saline to obtain DOX@EMP.

[0106] Example 12

[0107] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0108] S1, take 400 μL of 4×10 8 Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 300V, time 8ms, electric shock number 8 times, interval time 10s;

[0109] S2. Dilute the red blood cell suspension with 30 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 500 μL of 10 mg / mL DOX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (300 J / m 2 ) for 1.5 h;

[0110] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 20 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0111] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 1800 × g at 4°C for 15 min to remove red blood cells; take the supernatant, centrifuge at 13000 × g at 4°C for 5 min to remove cell debris; take the supernatant, centrifuge at 13000 × g at 4°C for 1.5 h, wash the precipitate twice with saline to obtain DOX@EMP.

[0112] Embodiment 13

[0113] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0114] S1, take 400 μL of 3×10 8 Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 300V, time 8ms, electric shock number 8 times, interval time 10s;

[0115] S2. Dilute the red blood cell suspension with 30 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 500 μL of 50 mg / mL MTX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (300 J / m 2 ) for 1.5 h;

[0116] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 20 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0117] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 2000 × g at 4°C for 10 min to remove red blood cells; take the supernatant, centrifuge at 14000 × g at 4°C for 2 min to remove cell debris; take the supernatant, centrifuge at 14000 × g at 4°C for 1 h, wash the precipitate twice with physiological saline to obtain MTX-loaded erythrocyte-derived microparticle (MTX@EMP).

[0118] Embodiment 14

[0119] A red blood cell drug-loaded microparticle is prepared according to the following steps:

[0120] S1, take 400 μL of 3×10 8Transfer the red blood cell suspension of 100 / mL into a 2mm electric shock cup, and place the electric shock cup into the electric shock tank of the Bio-rad Gene PulserXcell electroporation system. Use the following program to treat the cells: square wave, voltage 300V, time 8ms, electric shock number 8 times, interval time 10s;

[0121] S2. Dilute the red blood cell suspension with 30 mL of RPMI 1640 culture medium containing 10% fetal bovine serum, add 500 μL of 40 mg / mL MTX, mix well, and transfer to a 15 cm culture dish. Place the culture dish with the lid open in a biosafety cabinet under ultraviolet light (300 J / m 2 ) for 1.5 h;

[0122] S3, the red blood cell suspension irradiated by ultraviolet light is placed in a carbon dioxide incubator for 20 hours to allow the red blood cells to slowly release the drug-loaded microparticles;

[0123] S4. Transfer all the liquid in the culture dish to a 50 mL centrifuge tube, centrifuge the cell suspension at 2000 × g at 4°C for 10 min to remove red blood cells; take the supernatant, centrifuge at 14000 × g at 4°C for 2 min to remove cell debris; take the supernatant, centrifuge at 14000 × g at 4°C for 1 h, wash the precipitate twice with saline to obtain MTX@EMP.

[0124] Since Examples 1 to 14 all prepared red blood cell drug-loaded microparticles with the expected effects of the present invention, and the preparation effects are basically the same, the red blood cell drug-loaded microparticles prepared by the present invention are studied using Examples 1 and 13 as examples.

[0125] 1. Nanoparticle tracking analysis to measure the particle size distribution and concentration of red blood cell drug-loaded microparticles

[0126] The erythrocyte drug-loaded microparticles were resuspended in 500 μL of physiological saline and diluted 100 times, and then nanoparticle tracking analysis (NTA) was used to measure the particle size distribution and concentration of the erythrocyte drug-loaded microparticles.

[0127] The results show that the diameter of DOX@EMP is between 100 and 500 nm, with the highest concentration at 180 nm ( Figure 1 ); the concentration of DOX@EMP is 3.8×10 8 / mL. The diameter of MTX@EMP ranges from 105 to 480 nm, with the highest concentration at 141 nm. The concentration of MTX@EMP is 4.5×10 8 Pieces / mL.

[0128] 2. Electron microscopic observation of the morphology of red blood cell drug-loaded microparticles

[0129] The morphology of the red blood cell drug-loaded microparticles was detected by transmission electron microscopy. The results showed that the diameter of the red blood cell drug-loaded microparticles was about 200nm and was vesicle-like ( Figure 2 ).

[0130] 3. Flow cytometry detection of drug loading rate of DOX@EMP

[0131] DOX has red fluorescence, and the red blood cell microparticles carrying DOX also have red fluorescence. The drug loading rate of DOX@EMP was detected using the PE channel of a flow cytometer.

[0132] The results showed that more than 95% of the red blood cell microparticles were loaded with DOX ( Figure 3 ).

[0133] 4. Detection of drug loading of red blood cell drug-loaded microparticles by high performance liquid chromatography

[0134] After the red blood cell drug-loaded microparticles were lysed, the drug loading amount of the red blood cell drug-loaded microparticles was detected by high performance liquid chromatography.

[0135] The results show that 1×10 8 Each DOX@EMP contains 1.3 μg of DOX, and 1×10 8 Each MTX@EMP contained 1.9 μg of MTX.

[0136] Embodiment 15

[0137] Preparation of human red blood cell drug-loaded microparticles

[0138] The difference between Example 15 and Example 1 is that the red blood cells used are derived from peripheral blood drawn from human elbow vein, and the other steps are the same as Example 1.

[0139] The particle size of human erythrocyte drug-loaded microparticles was detected by NTA. The results showed that the diameter of human erythrocyte drug-loaded microparticles carrying DOX was between 120 and 450 nm, with the highest concentration at 188 nm and a concentration of 4.5×10 8 The diameter of the human red blood cell drug-loaded microparticles carrying MTX ranges from 160 to 480 nm, with the highest concentration at 225 nm, and a concentration of 3.9×10 8 Pieces / mL.

[0140] The morphology of human erythrocyte drug-loaded microparticles was detected by transmission electron microscopy, and the results showed that the diameter of human erythrocyte drug-loaded microparticles was about 200nm and they were vesicle-shaped.

[0141] The results of HPLC showed that 1×10 8 Each human red blood cell drug-loaded microparticle carrying DOX contains 1.5 μg of DOX, and 1×10 8Each human red blood cell drug-loaded microparticle carrying MTX contains 2.2 μg of MTX.

[0142] Comparative Example 1

[0143] Comparative Example 1 adds a step of co-incubating the chemotherapeutic drug with erythrocytes on the basis of Example 1, that is, after the erythrocyte suspension is mixed with DOX, the cells are incubated at 37° C. for 3 h. The other steps are the same as those in Example 1. The drug loading rate of the erythrocyte drug-loaded microparticles is detected by flow cytometry, and the concentration of the erythrocyte drug-loaded microparticles is detected by NTA.

[0144] The results showed that after adding the step of co-incubation of chemotherapy drugs with red blood cells, the drug loading rate of red blood cell drug-loaded microparticles was 94.8% and the concentration was 3.5×10 8 / mL, the drug loading rate and concentration are not significantly different from those in Example 1, indicating that this step is not necessary for preparing red blood cell drug-loaded microparticles and can be simplified. The present invention uses the optimized red blood cell drug-loaded microparticle preparation method to improve work efficiency.

[0145] Comparative Example 2

[0146] The difference between Comparative Example 2 and Example 1 is that in the electroporation conditions, an exponential wave is used instead of a square wave; the other steps are the same as those in Example 1.

[0147] The results of flow cytometry and NTA assays showed that the drug loading rate of red blood cell drug-loaded microparticles prepared by exponential wave was 14.5% ( Figure 3 ), the concentration is 1.7×10 6 / mL, the drug loading rate and concentration are much lower than those of the red blood cell drug-loaded microparticles provided by the present invention. The reason for this difference may be that exponential wave electroporation easily leads to the death of red blood cells; while square wave electroporation can not only effectively deliver drugs, but also well protect cells and maintain cell activity.

[0148] Comparative Example 3

[0149] The difference between Comparative Example 3 and Example 1 is that the cells used are mouse H22 liver cancer cells, and the other steps are the same as those in Example 1 to prepare H22 cell microparticles encapsulating DOX (DOX@H22-MP).

[0150] Experimental Example 1

[0151] DNA was extracted from DOX@H22-MP and DOX@EMP using the method provided by Chinese patent CN 115125238 A. RNA was extracted from DOX@H22-MP and DOX@EMP using the classic TRIZOL method. Nucleic acids were detected by agarose gel electrophoresis.

[0152] The results showed that DOX@H22-MP contained DNA and RNA fragments, while DOX@EMP did not contain DNA and RNA fragments ( Figure 4 ). The red blood cell drug-loaded microparticles prepared by the present invention do not contain nucleic acid, thereby avoiding the potential harm caused by delivering nucleic acid to the recipient cells during the tumor treatment process.

[0153] Experimental Example 2

[0154] Tumor cells phagocytize red blood cell drug-loaded microparticles

[0155] 1 × 10 5 H22 cells, add 1×10 8 DOX@EMP or PKH26-stained MTX@EMP was used as the control. After 8 h, flow cytometry was used to detect the phagocytosis of erythrocyte-loaded microparticles by H22 cells.

[0156] The results showed that more than 96% of tumor cells engulfed DOX@EMP( Figure 5 A), nearly 98% of tumor cells engulfed MTX@EMP ( Figure 5 B), indicating that the red blood cell drug-loaded microparticles prepared by the present invention can be effectively phagocytosed by tumor cells.

[0157] Experimental Example 3

[0158] Erythrocyte drug-loaded microparticles kill tumor cells

[0159] 1 × 10 5 H22 cells, add 1×10 8 DOX@EMP or MTX@EMP was added, and 48 h later, flow cytometry was used to detect tumor cell apoptosis.

[0160] The results showed that more than 70% of tumor cells underwent apoptosis ( Figure 6 ), indicating that the red blood cell drug-loaded microparticles prepared by the present invention can effectively kill tumor cells.

[0161] Experimental Example 4

[0162] Treatment of tumor-bearing mice with red blood cell-loaded microparticles

[0163] BALB / c mice were injected intraperitoneally with 1×10 5 H22 cells were used to construct the BALB / c mouse peritoneal tumor model. On day 1, the BALB / c mouse peritoneal tumor model was divided into 5 groups, with 8 mice in each group. The mice in the control group were injected with 200 μL of normal saline, and the mice in the DOX@EMP group were injected with 5×10 8 Mice in the DOX@EMP group were injected with 5×10 8MTX@EMP, and mice in the DOX group were injected with 6.5 μg DOX (compared with 5×10 8 The amount of DOX carried by each DOX@EMP was equivalent to that of DOX in the MTX group. The mice in the MTX group were injected with 9.5 μg MTX (equivalent to 5×10 8 The amount of DOX carried by each MTX@EMP was equivalent). The mice were injected again on the second day. The survival time of the mice was observed until the 50th day.

[0164] The results showed that the survival time of mice in the red blood cell drug-loaded microparticle group was significantly longer than that of mice in the chemotherapy drug group alone ( Figure 7 ), indicating that the tumor treatment effect of the red blood cell drug-loaded microparticles prepared by the present invention is better than that of chemotherapy drugs alone.

[0165] Experimental Example 5

[0166] Chemotaxis of erythrocyte-loaded drug-loaded microparticles on immune cells

[0167] BALB / c mice were injected intraperitoneally with 5×10 8 DOX@EMP or MTX@EMP was added to the mice. 24 hours later, flow cytometry was used to analyze the changes in the number of various immune cells in the mouse peritoneal cavity.

[0168] The results showed that injection of red blood cell-loaded microparticles could attract a large number of neutrophils into the peritoneal cavity ( Figure 8 ), while the number of other types of immune cells did not change much.

[0169] Experimental Example 6

[0170] The killing effect of neutrophils chemotactic by erythrocyte-loaded drug microparticles on tumors

[0171] BALB / c mice were injected intraperitoneally with 5×10 8 DOX@EMP or MTX@EMP, and 24 hours later, the peritoneal and bone marrow neutrophils were separated by magnetic bead sorting. 1×10 4 H22 cells, and then 2×10 5 Peritoneal neutrophils or bone marrow neutrophils were collected. After 48 hours, tumor cell apoptosis was detected.

[0172] The results showed that peritoneal neutrophils chemotactic to erythrocyte-loaded drug-loaded microparticles could effectively kill tumor cells, while bone marrow-derived neutrophils had no such effect ( Fig. 9 ), indicating that the neutrophils chemotactic by the red blood cell-loaded drug microparticles have the activity of killing tumor cells.

[0173] The above results show that the red blood cell drug-loaded microparticles prepared by the present invention can not only directly kill tumor cells, but also stimulate the body's neutrophils to participate in anti-tumor immune response, play a dual role of chemotherapy and immunotherapy, and make tumor treatment more efficient.

[0174] It should be noted that when the claims of the present invention involve numerical ranges, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. In order to avoid redundancy, the present invention describes a preferred embodiment.

[0175] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0176] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A red blood cell drug-loaded microparticle, characterized in that Follow these steps to prepare: Treating a suspension of red blood cells by electroporation, adding a drug, and obtaining a mixture; irradiating the mixture with ultraviolet light, culturing after irradiation to allow the red blood cells to release the drug-loaded microparticles, and performing differential centrifugation to obtain red blood cell drug-loaded microparticles; The electroporation treatment is performed by using a square wave at a voltage of 200V to 300V, and the ultraviolet irradiation is performed at an intensity of 280J / m 2 ~330J / m 2 Irradiate for 1h to 1.5h.

2. The red blood cell drug-loaded microparticles according to claim 1, characterized in that: The UV radiation intensity is 300J / m 2 , the irradiation time is 1.5h.

3. The red blood cell drug-loaded microparticles according to claim 1, characterized in that: The parameters for treating the red blood cell suspension by electroporation were set as follows: square wave, voltage 200V-300V, time 5ms-10ms, number of electric shocks 5-8 times, and interval time 7s-10s.

4. The red blood cell drug-loaded microparticles according to claim 1, characterized in that: The culture is carried out in a carbon dioxide incubator for 18 to 24 hours.

5. The red blood cell drug-loaded microparticles according to claim 1, characterized in that: The drug is doxorubicin or methotrexate.

6. The red blood cell drug-loaded microparticles according to claim 5, characterized in that: The concentration of red blood cell suspension was 3×10 8 / mL~5×10 8 / mL, the volume ratio of doxorubicin with a mass concentration of 5mg / mL to 10mg / mL or methotrexate with a mass concentration of 40mg / mL to 50mg / mL to the red blood cell suspension is 4-5:3.5-4.

7. The red blood cell drug-loaded microparticles according to claim 1, characterized in that: The differential centrifugation is carried out according to the following steps: The culture medium is centrifuged at 1800×g-2000×g and 4°C for 10min-15min to remove red blood cells; the supernatant is taken and centrifuged at 13000×g-14000×g and 4°C for 2min-5min to remove cell debris; the supernatant is taken and centrifuged at 13000×g-14000×g and 4°C for 1h-1.5h, and the resulting precipitate is the red blood cell drug-loaded microparticles.

8. A composition, characterized in that It comprises the red blood cell drug-loaded microparticles according to any one of claims 1 to 7.

9. Use of the red blood cell drug-loaded microparticles according to any one of claims 1 to 7 or the composition according to claim 8 in the preparation of anti-tumor drugs.

10. Use of the red blood cell drug-loaded microparticles according to any one of claims 1 to 7 or the composition according to claim 8 in the preparation of a drug for stimulating an immune response in a tumor patient.